Gait Rehabilitation Post Stroke:the Long Term Effect of Two Walking Aids -Canes and TheraTogs
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01366729 |
Recruitment Status :
Terminated
(Unable to recruite enough subjects to reach statistical power)
First Posted : June 6, 2011
Last Update Posted : December 29, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background 9000 people a year in Switzerland suffer a first time stroke. Of these 20 to 30% remain unable to walk and up to 60% are left with moderate to severe walking disability.
Evidence shows that rehabilitation techniques which emphasise use of the hemiplegic side influence ipsilesional cortical plasticity and improve functional outcomes. Canes are commonly used in gait rehabilitation although they significantly reduce hemiplegic muscle activity. We have shown that an orthosis "TheraTogs" ( elastic corset supporting hemiplegic side) significantly increases hemiplegic muscle activity during gait.
To date no clinical studies have investigated the long term effects of these techniques on gait recovery following stroke.
This study aims to determine if advances in the understanding of cortical plasticity and its relation to functional recovery following stroke can be applied to clinical gait rehabilitation to improve long term outcomes.
Hypotheses Early gait rehabilitation with canes will reduce hemiplegic muscle activity and inhibit balance reactions. In the long term this causes poorer walking ability and balance and consequently reduced social participation.
Early gait rehabilitation with TheraTogs will increase hemiplegic muscle activity and facilitate balance reactions. In the long term this improves walking ability and balance leading to increased social independence and participation.
Design Multi-centred, single blind, randomized control trial. Subjects 120 first time stroke patients Intervention When subjects can walk unaided on even ground whilst requiring verbal prompts and stand-by help without body contact (FAC 3) they will be randomly allocated into intervention (TheraTogs) or control (cane) group. TheraTogs will be applied to support hip extensor and abductor musculature according to a standardized procedure. Cane walking with cane at the level of the radial styloid of the sound wrist. Subjects will walk throughout the day with the assigned walking aid. Standard therapy treatments and usual care will remain unchanged and documented.The intervention will continue for five weeks or until patients have reached FAC 5 (independent walkers on all surfaces).
Measures: the day before intervention begin, the day after intervention completion (max 5 weeks), 3 months, 6 months and 2 years after completion Primary outcome Timed "up and go" test Secondary outcomes surface EMG of hemiplegic lower extremity musculature, temporo-spatial gait parameters, hip kinematics, dynamic balance. The Stroke Impact Scale.
Results Significance levels will be 5% with 95% CI's. ITT analyses will be performed. Descriptive statistics will be presented. Relevant co-variables will be identified and analysed. Discussion This study could have significant implications for the clinical practice of gait rehabilitation after stroke in particular the effect and appropriate use of walking aids
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke Gait Rehabilitation | Device: TheraTogs Device: Cane walking | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | How to Improve Walking, Balance and Social Participation Following Stroke: a Comparison of Cane Walking to an Orthosis TheraTogs in Early Post-stroke Gait Rehabilitation. A Multi-centred, Single Blind,Randomized Control Trial. |
Study Start Date : | November 2011 |
Actual Primary Completion Date : | August 2015 |
Actual Study Completion Date : | August 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: TheraTogs |
Device: TheraTogs
Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep. |
Active Comparator: Cane walking |
Device: Cane walking
All walking activities must take place with cane from waking until sleeping |
- Timed "up and go" test [ Time Frame: the day after intervention completion (max 5 weeks) ]
- surface EMG of hemiplegic lower extremity musculature [ Time Frame: the day after intervention completion (max 5 weeks) ]peak surface EMG of gluteus maximus and medius
- temporo-spatial gait parameters [ Time Frame: the day after intervention completion (max 5 weeks) ]
- hip kinematics [ Time Frame: the day after intervention completion (max 5 weeks) ]hemiplegic hip kinematic measurements in sagital and frontal planes
- Dynamic balance [ Time Frame: the day after intervention completion (max 5 weeks) ]Sway Star
- The Stroke Impact Scale [ Time Frame: the day after intervention completion (max 5 weeks) ]
- EMG activation patterns of hemiplegic leg musculature [ Time Frame: 1 day post intervention completion (max 5 weeks) ]EMG activation patterns of gluteus maximus, medius, vastus lateralis, semitendinosis, gastrocnemius and tibialis anterior
- Accelerometer Activity Monitoring [ Time Frame: Immediately post intervention ]The accelerometer (Aipermon® GmbH, Germany) will be attached to the patient's belt and positioned above the left hip. Patients will wear the device during waking hours during intervention time. The accelerometer will be attached after dressing in the morning and only taken off for showering, bathing and sleeping. In the statistical analysis a day starts at 24.00 o'clock and ends at 23.59 o'clock the same day. Mean activity per day will be calculated

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with hemiplegia following a first unilateral stroke
- will score at least level 3 on the Functional Ambulation Category (FAC) (able to walk unaided on even ground but requiring verbal prompts and stand-by help without body contact)
- must have been independent walkers prior to insult without walking aids
- Subjects will have a Mini Mental State score of 22 or above
Exclusion Criteria:
- orthopaedic or other neurological conditions that could limit walking ability
- no gross visuospatial or visual field deficits
- no medical contraindications to walking

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01366729
Switzerland | |
RehaClinic Bad Zurzach | |
Zurzach, Aargau, Switzerland | |
Felix Platterspital | |
Basel, Basel-Stadt, Switzerland, 4012 | |
Kantonsspital Luzern | |
Luzern, Switzerland |
Principal Investigator: | Clare C Maguire, MSc PT | Technical University of Bern, Bildungszentrun Gesundheit, Basel-Stadt |
Responsible Party: | Clare Maguire, Principal researcher, Technical University of Bern |
ClinicalTrials.gov Identifier: | NCT01366729 |
Other Study ID Numbers: |
TTvS_13DPD6_134993_BFHBZG |
First Posted: | June 6, 2011 Key Record Dates |
Last Update Posted: | December 29, 2022 |
Last Verified: | December 2022 |
hemiplegia walking canes TheraTogs |
EMG balance Timed up and go |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |